Change in plasma cryptococcal antigen titer is not associated with survival among human immunodeficiency virus-infected persons receiving preemptive therapy for asymptomatic cryptococcal antigenemia

Matthew F. Pullen, Francis Kakooza, Elizabeth Nalintya, Agnes N. Kiragga, Bozena M. Morawski, Radha Rajasingham, Anthony Mubiru, Yukari C. Manabe, Jonathan E. Kaplan, David B. Meya, David R. Boulware

Research output: Contribution to journalLetterpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)353-355
Number of pages3
JournalClinical Infectious Diseases
Volume70
Issue number2
DOIs
StatePublished - Jan 15 2020

Bibliographical note

Funding Information:
Financial support. This work was supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) though the Centers for Disease Control and Prevention (grant number U01GH000517).

Funding Information:
Potential conflicts of interest. M. F. P., D. R. B., D. B. M., E. N., and R. R. have received grant support from the National Institute of Allergy and Infectious Diseases. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

PubMed: MeSH publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

Cite this